Skip to main content
CND In the News

A Roundup of Syn-One Study Results Coverage from AAN 2023

By May 18, 2023June 1st, 2023No Comments

A Roundup of Syn-One Study Results Coverage from AAN 2023

Topline results from the Synuclein-One Study, presented at the American Academy of Neurology Annual Meeting in Boston April 22-27, were covered by several news outlets over the past two weeks. In the study, the Syn-One Test® demonstrated higher sensitivity and specificity than any alpha-synuclein biomarker test to date. The Synuclein-One Study also highlighted the safety and convenience of using skin biopsies to detect alpha-synuclein.

A write-up of the study appeared on NeurologyLive along with an interview with CND Life Sciences’ Chief Medical Officer and Co-Founder, Dr. Todd Levine, about the role of the Syn-One Test in diagnosing neurodegenerative disorders. Additional coverage about the test’s high sensitivity rate and clinical impact appeared in MedicalDevice Network and Parkinson’s News Today.

CND Life Sciences

CND Life Sciences is the creator of the Syn-One Test™, the world’s first commercially available test to visualize abnormal, phosphorylated alpha-synuclein in cutaneous nerve fibers. The test is an objective, evidence-based diagnostic tool to aid in the diagnosis of Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, pure autonomic failure, or REM sleep behavior disorder.